You can buy or sell Alkermes and other stocks, options, ETFs, and crypto commission-free!
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. Read More The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
52 Week High
52 Week Low
UPDATE: Urovant Sciences (UROV) Appoints James Robinson to Board
(Updated - March 6, 2019 8:02 AM EST) Urovant Sciences (NASDAQ: UROV) today announced James Robinson, President and Chief Operating Officer of Alkermes, will join its Board of Directors. “Jim’s extensive leadership, knowledge and experience in the biopharmaceutical space combined with his unique understanding of the urology market will help inform Urovant’s strategies and growth opportunities,” said Keith A. Katkin, Chief Executive Officer of Urovant. “Urovant is pleased to welcome him to our board and my...
PR NewswireMar 5
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference
DUBLIN, March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39th Annual Health Care Conference on Tuesday, Mar.
Yahoo FinanceFeb 28
Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunoco LP (SUN), Citrix Systems, Inc. (CTXS), Alkermes plc (ALKS), CubeSmart (CUBE), Morningstar, Inc. (MORN), and Synopsys, Inc. (SNPS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. Complimentary Access: Research Re...
Expected Apr 25, Pre-Market